(Q38223323)

31 August 2017

Chronic kidney disease: targeting prostaglandin E2 receptors (English)

1 reference

chronic renal insufficiency

31 August 2017

1 reference

1 reference

Rania Nasrallah

1

1 reference

PubMed ID

24966087

31 August 2017

Ramzi Hassouneh

series ordinal

2

1 reference

PubMed ID

24966087

31 August 2017

Richard L Hébert

series ordinal

3

1 reference

31 August 2017

25 June 2014

1 reference

American Journal of Physiology - Renal Physiology

31 August 2017

1 reference

31 August 2017

307

1 reference

31 August 2017

3

1 reference

31 August 2017

F243-50

1 reference

Role of EP(2) and EP(3) PGE(2) receptors in control of murine renal hemodynamics

31 August 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Opposed effects of prostaglandin E2 on perfusion of rat renal cortex and medulla: interactions with the renin-angiotensin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

EP4: a new piece in the fibrotic puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Hyperfiltration and effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Novel targets of antifibrotic and anti-inflammatory treatment in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

The obligatory role of the kidney in long-term arterial blood pressure control: extending Guyton's model of the circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

The pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

PGE(2) induces COX-2 expression in podocytes via the EP(4) receptor through a PKA-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Mechanical stretch and prostaglandin E2 modulate critical signaling pathways in mouse podocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Temporal expression of the PGE2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Renal β-intercalated cells maintain body fluid and electrolyte balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Efferent arterioles exclusively express the subtype 1A angiotensin receptor: functional insights from genetic mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Proteinuria in diabetic kidney disease: a mechanistic viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

A glimpse of various pathogenetic mechanisms of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Hypertonicity stimulates PGE2 signaling in the renal medulla by promoting EP3 and EP4 receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Prostaglandin E2 promotes cellular recovery from established nephrotoxic serum nephritis in mice, prosurvival, and regenerative effects on glomerular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

21 January 2018

Chronic kidney disease

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Prostaglandin E(2) mediates proliferation and chloride secretion in ADPKD cystic renal epithelia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Kidney proximal tubular epithelial-specific overexpression of netrin-1 suppresses inflammation and albuminuria through suppression of COX-2-mediated PGE2 production in streptozotocin-induced diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Prostaglandins in the kidney: developments since Y2K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2(Akita) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Celecoxib modifies glomerular basement membrane, mesangium and podocytes in OVE26 mice, but ibuprofen is more detrimental

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Renal prostaglandin E2 receptor (EP) expression profile is altered in streptozotocin and B6-Ins2Akita type I diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

The role of inflammatory cytokines in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Intercellular Adhesion Molecule-1–Deficient Mice Are Resistant Against Renal Injury After Induction of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Is there a role for PGE2 in urinary concentration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Renal effects on a solitary kidney of specific inhibition of cyclooxygenease-2 after 24 h of complete ureteric obstruction in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

EP1c times for angiotensin: EP1 receptors facilitate angiotensin II-induced vascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

EP(1) and EP(4) receptors mediate prostaglandin E(2) actions in the microcirculation of rat kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

PGE2 causes mesangial cell hypertrophy and decreases expression of cyclin D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Increased severity of renal impairment in nephritic mice lacking the EP1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Prostaglandin E2 mediates connecting tubule glomerular feedback

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Cell signaling. H2O2, a necessary evil for cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Pathogenic perspectives for the role of inflammation in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

The RAAS in the pathogenesis and treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Activation of prostaglandin E2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Kidney disease in diabetology: lessons from 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

NADPH oxidases, reactive oxygen species, and the kidney: friend and foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Oxidative stress, anti-oxidant therapies and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Fluid flow shear stress upregulates prostanoid receptor EP2 but not EP4 in murine podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

A maladaptive role for EP4 receptors in podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Prostaglandin E2 modulation of blood pressure homeostasis: studies in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

The prostaglandin E2 analogue sulprostone antagonizes vasopressin-induced antidiuresis through activation of Rho.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Biphasic actions of prostaglandin E(2) on the renal afferent arteriole : role of EP(3) and EP(4) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

The pathogenic role of the renal proximal tubular cell in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

PTGER1 deletion attenuates renal injury in diabetic mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Chronic kidney disease and mortality risk: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

The proximal tubule in the pathophysiology of the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Direct vasoconstrictor effect of prostaglandin E2 on renal interlobular arteries: role of the EP3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

The role of epigenetics in the pathology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Prostaglandin E2 EP3 receptor regulates cyclooxygenase-2 expression in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Inflammation and the pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Glycemic management in ESRD and earlier stages of CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

GW501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Renin-Angiotensin system - considerations for hypertension and kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

The prostanoid EP4 receptor and its signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Prostaglandin EP2 and EP4 receptors modulate expression of the chemokine CCL2 (MCP-1) in response to LPS-induced renal glomerular inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Genetic deletion of the P2Y2 receptor offers significant resistance to development of lithium-induced polyuria accompanied by alterations in PGE2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00224.2014

10.1152/AJPRENAL.00224.2014

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24966087